CAR-T cell therapy in China
Transcript of CAR-T cell therapy in China
![Page 1: CAR-T cell therapy in China](https://reader035.fdocuments.us/reader035/viewer/2022081414/587ea5681a28ab2a4a8b68d7/html5/thumbnails/1.jpg)
Department of Hematology Sheng Jing Hospital of China Medical University
Wang Hong-tao MD & PhD
1
![Page 2: CAR-T cell therapy in China](https://reader035.fdocuments.us/reader035/viewer/2022081414/587ea5681a28ab2a4a8b68d7/html5/thumbnails/2.jpg)
2Brchireddy P, et al. Nat Rev Cancer. 2015;15(4):201-15.
![Page 3: CAR-T cell therapy in China](https://reader035.fdocuments.us/reader035/viewer/2022081414/587ea5681a28ab2a4a8b68d7/html5/thumbnails/3.jpg)
3James N, et al. Nat Rev Clin Oncol. 2013;10:267-76.
![Page 4: CAR-T cell therapy in China](https://reader035.fdocuments.us/reader035/viewer/2022081414/587ea5681a28ab2a4a8b68d7/html5/thumbnails/4.jpg)
4James N, et al. Nat Rev Clin Oncol. 2013;10:267-76.
![Page 5: CAR-T cell therapy in China](https://reader035.fdocuments.us/reader035/viewer/2022081414/587ea5681a28ab2a4a8b68d7/html5/thumbnails/5.jpg)
A Rambaldi, et al. Leukemial. 2015;29:1-10.5
![Page 6: CAR-T cell therapy in China](https://reader035.fdocuments.us/reader035/viewer/2022081414/587ea5681a28ab2a4a8b68d7/html5/thumbnails/6.jpg)
6
![Page 7: CAR-T cell therapy in China](https://reader035.fdocuments.us/reader035/viewer/2022081414/587ea5681a28ab2a4a8b68d7/html5/thumbnails/7.jpg)
7
CAR-T therapy in our centerDisease
LymphomaTarget antigen
CD19Vector
RetrovirusChemotherapy administered before cell
infusionFludarabine and cyclophosphamide
![Page 8: CAR-T cell therapy in China](https://reader035.fdocuments.us/reader035/viewer/2022081414/587ea5681a28ab2a4a8b68d7/html5/thumbnails/8.jpg)
8
CAR-T therapy in our centerPatie
ntGende
r Age (year
s)Diagnosis
Number of prior
therapies
Number of CAR-T
cells infused
Response (duration in months after CAR-T cell infusion)
1 Female 55 DLBCL 10 25×107 PR (1)
2a* Female 30 DLBCL 11 6.6×107 PR (3)
2b* Female 30 DLBCL 11 5×107 SD (9)
3a* Male 41 DLBCL 11 18×107 PR (1)
3b* Male 41 DLBCL 11 19.6×107 CR (5)
4 Male 10 Burkitt’s Lymphoma 8 7×107 NE
5 Female 62 DLBCL 10 7.6×107 PR (2)
* Patient 2 and 3 were treated twice.Abbreviations: CAR, chimeric antigen receptor; DLBCL, diffuse large B cell lymphoma; PR, partial remission; CR, complete remission; NE, not evaluable for malignancy response because the patient died with sepsis.
![Page 9: CAR-T cell therapy in China](https://reader035.fdocuments.us/reader035/viewer/2022081414/587ea5681a28ab2a4a8b68d7/html5/thumbnails/9.jpg)
Clinical index
9
![Page 10: CAR-T cell therapy in China](https://reader035.fdocuments.us/reader035/viewer/2022081414/587ea5681a28ab2a4a8b68d7/html5/thumbnails/10.jpg)
10
Images
![Page 11: CAR-T cell therapy in China](https://reader035.fdocuments.us/reader035/viewer/2022081414/587ea5681a28ab2a4a8b68d7/html5/thumbnails/11.jpg)
Cytokine Release Syndrome
11
57.15% (4/7)Fever Neurologic toxicity (Patient 1)
PreventionTNF α antagonistCRRT?
![Page 12: CAR-T cell therapy in China](https://reader035.fdocuments.us/reader035/viewer/2022081414/587ea5681a28ab2a4a8b68d7/html5/thumbnails/12.jpg)
Cytokines
12
![Page 13: CAR-T cell therapy in China](https://reader035.fdocuments.us/reader035/viewer/2022081414/587ea5681a28ab2a4a8b68d7/html5/thumbnails/13.jpg)
Cytokines
13
![Page 14: CAR-T cell therapy in China](https://reader035.fdocuments.us/reader035/viewer/2022081414/587ea5681a28ab2a4a8b68d7/html5/thumbnails/14.jpg)
NK cells and B cells
14
![Page 15: CAR-T cell therapy in China](https://reader035.fdocuments.us/reader035/viewer/2022081414/587ea5681a28ab2a4a8b68d7/html5/thumbnails/15.jpg)
T cells
15
![Page 16: CAR-T cell therapy in China](https://reader035.fdocuments.us/reader035/viewer/2022081414/587ea5681a28ab2a4a8b68d7/html5/thumbnails/16.jpg)
Thanks !
16
2015.8.28